Literature DB >> 8906813

Development of CD4-CD8- alpha beta TCR+NK1.1+ T lymphocytes: thymic selection by self antigen.

R J Schulz1, A Parkes, E Mizoguchi, A K Bhan, S Koyasu.   

Abstract

Development of CD4-CD8- double negative (DN) alpha beta TCR+ cells were examined by cell transfer experiments using an Ly-5 congenic mouse system. Purified DN alpha beta TCR+ thymocytes injected intrathymically emigrated from the thymus to the spleen. The same cells did not return to the thymus when injected i.v. Similarly, peripheral DN alpha beta TCR+ cells from spleen and liver did not go to the thymus when injected i.v. but migrated to the spleen. These results indicate that DN alpha beta TCR+ thymocytes develop within the thymus and emigrate to peripheral organs. It is thus likely that peripheral DN alpha beta TCR+ cells are at least partly of thymic origin. DN alpha beta TCR+ thymocytes are unique in that they express a natural killer cell marker, NK1.1, which is not found on conventional T cells. We further examined the thymic selection of DN alpha beta TCR+NK1.1+ thymocytes by using an anti-HY TCR-transgenic (tg)/Rag-2(-/-) mouse system with H-2 backgrounds that were negative, positive, or nonselecting for conventional T cells. The number of DNtg TCR alpha beta+NK1.1+ cells was m prominent in male H-2b animals in which conventional T cells are deleted by HY/H-2Db recognition. Fewer DNtg TCR alpha beta+NK1.1+ cells were found in H-2b females (positive selecting background), and almost no DNtg TCR alpha beta+NK1.1+ cells were detected in H-2d animals (nonselecting background). Unlike conventional T cells, DNtg TCR alpha beta+NK1.1+ cells from anti-HY/Rag-2(-/-) H-2b mice express Fc(epsilon)RI(gamma) and CD3zeta as DN alpha beta TCR+NK1.1+ cells from normal C57BL/6 mice. Our results indicate that DNtg TCR alpha beta+NK1.1+ cells are positively selected by self Ag/MHC and emigrate to the peripheral organs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906813

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus.

Authors:  M Amagai; K Tsunoda; H Suzuki; K Nishifuji; S Koyasu; T Nishikawa
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  Intrathymic selection of NK1.1(+)alpha/beta T cell antigen receptor (TCR)+ cells in transgenic mice bearing TCR specific for chicken ovalbumin and restricted to I-Ad.

Authors:  C Iwabuchi; K Iwabuchi; K Nakagawa; T Takayanagi; H Nishihori; S Tone; K Ogasawara; R A Good; K Onoé
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

3.  Selection and adaptation of cells expressing major histocompatibility complex class I-specific receptors of the natural killer complex.

Authors:  A Bendelac
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

4.  A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus.

Authors:  M Falcone; B Yeung; L Tucker; E Rodriguez; N Sarvetnick
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307

5.  The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families.

Authors:  S H Park; A Weiss; K Benlagha; T Kyin; L Teyton; A Bendelac
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

6.  Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes.

Authors:  Datsen G Wei; Hyunji Lee; Se-Ho Park; Lucie Beaudoin; Luc Teyton; Agnès Lehuen; Albert Bendelac
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

7.  Developmentally regulated extinction of Ly-49 receptor expression permits maturation and selection of NK1.1+ T cells.

Authors:  H Robson MacDonald; R K Lees; W Held
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.